Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Primary thrombocythemia: diagnosis and therapy].

Petro E Petrides1

  • 1Hämatologisch-Onkologische Schwerpunktpraxis, München, Germany. petrides@onkologiemuenchen.de

Medizinische Klinik (Munich, Germany : 1983)
|August 10, 2006
PubMed
Summary

Primary thrombocythemia is a rare bone marrow disorder. Evidence-based guidelines and JAK2 V617F mutation analysis are advancing diagnosis and targeted therapies for this condition.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Primary Myelofibrosis (PMF)-The German ONKOPEDIA Guideline 2025.

International journal of cancer·2026
Same author

The German ONKOPEDIA Guideline for Myelofibrosis in 2025-Recommendations of an MPN Expert Panel of the German Society for Hematology and Oncology (DGHO).

International journal of cancer·2026
Same author

Guidelines for the management of acute porphyria: recommendations from the International Porphyria Network.

The Lancet. Haematology·2026
Same author

Real-World Experience With Givosiran in Acute Porphyrias: A Narrative Review and a Novel Hypothesis.

Cureus·2026
Same author

Successful Pregnancy After Combined Liver and Renal Transplantation in a Patient With Acute Intermittent Porphyria.

Case reports in transplantation·2025
Same author

Unraveling the germline inheritance of the <i>JAK2</i>F556V gene mutation in familial thrombocythemia: a comprehensive analysis of 11 family members and potential implications for surveillance.

Haematologica·2024

Area of Science:

  • Hematology
  • Oncology
  • Molecular Biology

Background:

  • Primary thrombocythemia is a rare, chronic myeloproliferative disorder characterized by elevated platelet counts and potential complications like thrombosis, hemorrhage, myelofibrosis, or acute leukemia.
  • Diagnosis involves assessing platelet count, morphology, bone marrow alterations, and excluding other myeloproliferative neoplasms.
  • Current management includes aspirin for thromboembolic prevention and cytoreductive or thromboreductive agents (hydroxyurea, interferon-alpha, anagrelide) based on risk factors and complications, necessitating careful risk-benefit analysis due to long-term therapy effects.
  • The JAK2 V617F mutation is identified in up to 50% of patients and is implicated in the disease's pathogenesis.

Purpose of the Study:

  • To compare the efficacy and safety of different therapeutic strategies for primary thrombocythemia.
  • To address the controversy surrounding treatment outcomes based on varying study designs.

Main Methods:

  • Two prospective randomized studies, the British PT1 and European ANAHYDRET, were conducted due to the rarity of primary thrombocythemia.
  • The PT1 study compared anagrelide plus aspirin with hydroxyurea plus aspirin.
  • The ANAHYDRET study compared monotherapy with hydroxyurea versus anagrelide.

Main Results:

  • The differing study designs have led to ongoing debate regarding the interpretation of results from these key clinical trials.
  • Further analysis is needed to definitively establish optimal treatment protocols.

Conclusions:

  • Randomized clinical studies are increasingly guiding evidence-based therapy, moving beyond expert opinion.
  • Advances in understanding the molecular basis, particularly the JAK2 V617F mutation, are improving molecular diagnostics and paving the way for targeted therapies.

Related Experiment Videos